Latest News

FDA approves LORBRENA for treatment of patients with ALK-positive metastatic NSCLC

Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved LORBRENA, a third-generation anaplastic lymphoma kinase tyrosine kinase inhibitor for patients with ALK-positive metastatic non-small cell lung cancer whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

Source link

Related posts

HPV Shot Rids 97-Year-Old of Advanced Skin Cancer


STAT Plus: Swiss government is asked to issue a compulsory license for a Roche cancer drug


Trump administration ends key drug pricing proposal


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy